You are here: Industry Insights > GlaxoSmithKline

News List

GlaxoSmithKline taking heat in its U.K. home turf over shortages of hepatitis B vaccine fiercepharma
August 23, 2017
GSK has confirmed the global shortage of the vaccine but declined to comment on any alleged disparity of supplies favoring the U.S. over the U.K.
GlaxoSmithKline partners with Alibaba for China HPV vaccine market grab fiercepharma
August 23, 2017
The new collaboration enables users to access online HPV and cervical cancer education information or consultation services.
GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery fiercebiotech
August 17, 2017
GlaxoSmithKline has inked its second AI-based drug discovery deal of the summer. While the partners kept details under wraps, Insilico Medicine has its own drug discovery programs for age-related diseases, as well as cancer, diabetes and ALS.
GSK jilts Ionis rare disease drug as FDA filing nears fiercebiotech
August 14, 2017
GlaxoSmithKline has jilted Ionis Pharmaceuticals just before the pair was due to file for approval of inotersen. The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.
Merck and GlaxoSmithKline production issues lead to global shortage of hepatitis B vaccine fiercepharma
August 10, 2017
A global shortage of vaccine to fight the hepatitis B virus had developed as both Merck & Co., and GlaxoSmithKline deal with manufacturing issues.
GlaxoSmithKline to cut 30 drug development programmes under plan to focus on four key areas firstwordpharma
July 27, 2017
GlaxoSmithKline announced alongside its second-quarter results that it plans to cut more than 30 clinical and preclinical drug development programmes, whilst considering options for its rare diseases unit, as it looks to improve the efficiency of its phar
GlaxoSmithKline's malaria shot set for WHO pilot test in Ghana, Kenya and Malawi fiercepharma
April 25, 2017
GlaxoSmithKline’s first-of-a-kind malaria vaccine Mosquirix will undergo real-world pilot studies in three African countries selected by the World Health Organization.
With new online tool, MSF invites Pfizer, GSK investors to weigh in on vaccine pricing fiercepharma
April 19, 2017
After years of protesting against Pfizer and GlaxoSmithKline’s pneumococcal vaccine pricing, Médecins Sans Frontières is empowering pharma investors to get involved.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page